Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
J Med Virol ; 85(6): 1063-8, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23588733

ABSTRACT

High-risk human papillomavirus (HPV) DNA detection provides high sensitivity but low specificity for moderate-grade cervical intraepithelial neoplasia or worse histological identification. A prospective study evaluated mRNA testing efficacy for predicting this histological diagnosis in case of HPV 16 and/or 18 DNA detection. A total of 165 endocervical samples harboring HPV 16 and/or 18 DNA were tested with NucliSENS-EasyQ® HPV E6/E7-mRNA-assay (Biomerieux, Marcy l´Etoile, France). Women with cytological alterations were referred to colposcopy (n = 111). Moderate-grade cervical intraepithelial neoplasia or worse was diagnosed in 25.8% of women presenting atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions and in 89.8% of women with high-grade squamous intraepithelial lesions. mRNA sensitivity was 81.3% and 84.1%, respectively. Specificity was 52.2%, and 80.0%, respectively. Negative predictive value (NPV) was 88.9% in undetermined or low-grade squamous lesions. Positive predictive value (PPV) was 97.4% in high-grade squamous lesions. mRNA reduced colposcopies by 44.3% in undetermined or low-grade squamous lesions. Direct treatment of mRNA-positive cases reduced 77.5% of colposcopies in high-grade squamous lesions. Women without cytological alterations were followed for 18 months (n = 35), and moderate-grade cervical intraepithelial neoplasia or worse was diagnosed in 34.3%; mRNA sensitivity and specificity were 83.3% and 86.9%, respectively. PPV and NPV were 76.9% and 90.9%, respectively for predicting moderate-grade cervical intraepithelial neoplasia or worse in 18 months. mRNA reduced the number of visits for follow-up in 62.2%. In conclusion, NucliSENS-EasyQ® HPV E6/E7-mRNA-assay (Biomerieux) can serve as a triage test in case of HPV 16 and/or 18 DNA detection.


Subject(s)
Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Papillomavirus Infections/diagnosis , RNA, Messenger/genetics , RNA, Viral/genetics , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Neoplasms/diagnosis , Adolescent , Adult , Aged , Cervix Uteri/pathology , Cervix Uteri/virology , Colposcopy , Diagnostic Tests, Routine , Female , Human papillomavirus 16/isolation & purification , Human papillomavirus 18/isolation & purification , Humans , Middle Aged , Oncogene Proteins, Viral/analysis , Oncogene Proteins, Viral/genetics , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Pregnancy , Prospective Studies , RNA, Messenger/analysis , RNA, Viral/analysis , Sensitivity and Specificity , Triage , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/virology
2.
Rev. iberoam. micol ; 30(1): 61-63, ene. 2013.
Article in Spanish | IBECS | ID: ibc-109135

ABSTRACT

Antecedentes. La vulvovaginitis candidiásica es una infección frecuente en mujeres jóvenes que se acompaña de alta morbilidad y elevados gastos sanitarios. Objetivos. Las candidiasis vaginales causadas por Candida glabrata constituyen un reto terapéutico dada la resistencia adquirida por muchas cepas de esta especie a los antifúngicos azólicos. Métodos. En este trabajo presentamos 2 casos de candidiasis vaginal complicada por Candida glabrata resistentes a fluconazol y tratadas con voriconazol. Resultados. Las 2 pacientes mejoraron tras la administración de voriconazol, 400mg/12h el primer día y posteriormente 200mg/12h durante 14 días, con desaparición de la sintomatología y la negativización de los cultivos. Conclusiones. En conclusión, los resultados obtenidos nos llevan a sugerir el uso del voriconazol como alternativa terapéutica en este tipo de candidiasis que, aunque no comprometen la vida, llevan asociada una elevada morbilidad(AU)


Background. Vulvovaginal candidosis is a common infection in young women, and it is associated with high morbidity and high health costs. Aims. Vulvovaginal candidosis caused by Candida glabrata is a therapeutic challenge due to the acquired resistance of many strains of this species to azole antifungals. Methods. We present two cases of vaginal candidosis complicated by fluconazole-resistant Candida glabrata, and treated with voriconazole. Results. Both patients improved after administration of voriconazole, 400mg/12h the first day and then 200mg every 12h for 14 days. Their symptoms disappeared and cultures became negative. Conclusions. These results suggest voriconazole can be used as a therapeutic alternative for this type of candidosis which, although not life threatening, is associated with a high morbidity(AU)


Subject(s)
Humans , Female , Adolescent , Young Adult , Vulvovaginitis/complications , Vulvovaginitis/diagnosis , Vulvovaginitis/therapy , Candida glabrata , Candida glabrata/isolation & purification , Candida glabrata/pathogenicity , Antifungal Agents/administration & dosage , Antifungal Agents/economics , Antifungal Agents/therapeutic use , Fluconazole/therapeutic use , Vulvovaginitis/microbiology , Indicators of Morbidity and Mortality , Azoles/economics , Azoles/therapeutic use
3.
Rev Iberoam Micol ; 30(1): 61-3, 2013 Jan 03.
Article in Spanish | MEDLINE | ID: mdl-22885618

ABSTRACT

BACKGROUND: Vulvovaginal candidosis is a common infection in young women, and it is associated with high morbidity and high health costs. AIMS: Vulvovaginal candidosis caused by Candida glabrata is a therapeutic challenge due to the acquired resistance of many strains of this species to azole antifungals. METHODS: We present two cases of vaginal candidosis complicated by fluconazole-resistant Candida glabrata, and treated with voriconazole. RESULTS: Both patients improved after administration of voriconazole, 400 mg/12 h the first day and then 200 mg every 12 h for 14 days. Their symptoms disappeared and cultures became negative. CONCLUSIONS: These results suggest voriconazole can be used as a therapeutic alternative for this type of candidosis which, although not life threatening, is associated with a high morbidity.


Subject(s)
Antifungal Agents/therapeutic use , Candida glabrata/drug effects , Candidiasis, Vulvovaginal/drug therapy , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Adult , Antifungal Agents/pharmacology , Candida glabrata/isolation & purification , Candidiasis, Vulvovaginal/microbiology , Cesarean Section , Drug Evaluation , Drug Resistance, Multiple, Fungal , Female , Fluconazole/pharmacology , Humans , Microbial Sensitivity Tests , Pregnancy , Puerperal Disorders/drug therapy , Puerperal Disorders/microbiology , Pyrimidines/pharmacology , Recurrence , Species Specificity , Treatment Outcome , Triazoles/pharmacology , Voriconazole , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...